Cytochroma names new CFO

Mr Wieland brings to Cytochroma nearly 40 years of experience in finance and financial management, at both public and private companies, and will be based in the company’s Illinois office.

Previous to Cytochroma, Mr Wieland was executive vice president and CFO of Advanced Life Sciences where he helped that company list on the NASDAQ stock market in 2005 and prepared it for Sarbanes-Oxley implementation.

Charles Bishop, Cytochroma’s president and CEO, said: “Mr Wieland joins Cytochroma at a critical inflection point in its growth. The company now has multiple Vitamin D-based therapies in clinical development and it requires a seasoned CFO who can play a key role in expanding and evolving the corporate and financial infrastructure.”